Cildraw M 50 Tablet combines Cilnidipine 10mg and Metoprolol 50mg, a potent antihypertensive combination designed for comprehensive blood pressure and heart rate management. This dual therapy helps reduce cardiovascular strain, improve cardiac output, and maintain optimal vascular health.
Cilnidipine, a calcium channel blocker, relaxes vascular smooth muscles, lowering peripheral resistance, while Metoprolol, a beta-blocker, reduces heart rate and cardiac workload. Together, they provide balanced and effective antihypertensive control.
This tablet is widely prescribed for patients with essential hypertension, angina, or high cardiovascular risk. Its dual-action mechanism ensures better blood pressure stability and improved patient outcomes, making it a preferred therapy in cardiology practices.
Adding Cildraw M 50 Tablet to your cardiology and antihypertensive segment enhances your product portfolio with a clinically trusted combination. It offers strong opportunities for hospital supply, retail pharmacy distribution, institutional tenders, export markets, and third-party manufacturing, ensuring consistent demand and profitability.